Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study ; volume:118 ; number:12 ; year:2018 ; pages:2188-2188
Thrombosis and haemostasis ; 118, Heft 12 (2018), 2188-2188
- Beteiligte Personen und Organisationen
-
Schulman, Sam
Gross, Peter L.
Ritchie, Bruce
Nahirniak, Susan
Lin, Yulia
Lieberman, Lani
Carrier, Marc
Crowther, Mark A.
Ghosh, Indy
Lazo-Langner, Alejandro
Zondag, Michelle
- DOI
-
10.1055/s-0038-1675417
- URN
-
urn:nbn:de:101:1-2019042107202495920119
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schulman, Sam
- Gross, Peter L.
- Ritchie, Bruce
- Nahirniak, Susan
- Lin, Yulia
- Lieberman, Lani
- Carrier, Marc
- Crowther, Mark A.
- Ghosh, Indy
- Lazo-Langner, Alejandro
- Zondag, Michelle
Ähnliche Objekte (12)
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery
Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Role of prothrombin complex concentrate in perioperative coagulation therapy
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery
Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Role of prothrombin complex concentrate in perioperative coagulation therapy
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery
Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Role of prothrombin complex concentrate in perioperative coagulation therapy
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial